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Background: Pregnant women who gain excess weight are at risk of complications during pregnancy and in the
long term. Interventions based on diet and physical activity minimise gestational weight gain with varied effect on
clinical outcomes. The effect of interventions on varied groups of women based on body mass index, age, ethnicity,
socioeconomic status, parity, and underlying medical conditions is not clear. Our individual patient data (IPD)
meta-analysis of randomised trials will assess the differential effect of diet- and physical activity-based interventions
on maternal weight gain and pregnancy outcomes in clinically relevant subgroups of women.
Methods/design: Randomised trials on diet and physical activity in pregnancy will be identified by searching the
following databases: MEDLINE, EMBASE, BIOSIS, LILACS, Pascal, Science Citation Index, Cochrane Database of
Systematic Reviews, Cochrane Central Register of Controlled Trials, Database of Abstracts of Reviews of Effects, and
Health Technology Assessment Database. Primary researchers of the identified trials are invited to join the
International Weight Management in Pregnancy Collaborative Network and share their individual patient data. We
will reanalyse each study separately and confirm the findings with the original authors. Then, for each intervention
type and outcome, we will perform as appropriate either a one-step or a two-step IPD meta-analysis to obtain
summary estimates of effects and 95% confidence intervals, for all women combined and for each subgroup of
interest. The primary outcomes are gestational weight gain and composite adverse maternal and fetal outcomes.
The difference in effects between subgroups will be estimated and between-study heterogeneity suitably quantified
and explored. The potential for publication bias and availability bias in the IPD obtained will be investigated. We will
conduct a model-based economic evaluation to assess the cost effectiveness of the interventions to manage
weight gain in pregnancy and undertake a value of information analysis to inform future research.
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Excessive weight gain in pregnancy is associated with
maternal and fetal complications such as pre-eclampsia,
gestational diabetes, caesarean section, large for gesta-
tional age babies [1-8], and postpartum weight retention
[9,10]. It is a risk factor for maternal and childhood
obesity in the long term [5,9,11], resulting in significant
burden to the health care systems globally [9,10,12-17].
In the UK, obesity costs the National Health Service
(NHS) around £4 billion a year and the economy a further
£16 billion in indirect costs [18,19]. Reducing excessive
weight gain in pregnancy by effective weight management
programmes could lead to significant societal advantages
in terms of health and costs.
In the antenatal period, women are in regular contact
with health professionals and are highly motivated to
make changes that may improve their pregnancy out-
comes [20]. Our study-level meta-analysis of 44 rando-
mised trials showed that dietary and lifestyle interventions
were effective in reducing weight gain in pregnancy and
reduced risk of adverse outcomes [21]. We were restricted
by unexplained heterogeneity of effects and paucity of
published detail from making firm recommendations for
clinical practice, especially for pregnancy outcomes. Im-
portantly, we were unable to ascertain if the intervention
had a differential beneficial effect on particular subgroups
of women.
The only guidance on weight gain recommendations
in pregnancy is by the Institute of Medicine (IOM) in
the US, which is based on observational evidence. The
UK and other European policy makers do not recom-
mend specific weight gain targets in pregnancy due to
the absence of robust evidence. The Public Health Inter-
ventions Advisory Committee (PHIAC) in the UK has
prioritised the need for research to identify the most ef-
fective and cost-effective ways of helping women to ma-
nage their weight during pregnancy, including women
who are obese, those who are under 18 and those from
disadvantaged, low income and minority ethnic groups
[22]. Additionally, they highlighted the need to ascertain
whether adherence to IOM recommendations on gesta-
tional weight gain improves obstetric outcomes, espe-
cially in minority groups and teenagers.
We plan to undertake an individual patient data (IPD)
meta-analysis [23] to robustly address the above ques-
tions on the effect of weight management interventions
in women stratified by BMI, ethnicity, socioeconomic
status and teenage pregnancies by obtaining raw patient-
level data for synthesis across trials.
Objectives
The primary objective of this IPD meta-analysis is to de-
termine the differential effects of weight management
interventions in pregnancy on maternal weight gainand composite adverse maternal and fetal outcomes in
women according to their (i) body mass index (BMI),
(ii) age, (iii) ethnicity, (iv) parity, and (v) underlying
medical conditions.
The secondary objectives are to:
i. Validate weight change as an outcome measure by
quantifying the relationship between the amount
of weight gained in pregnancy and the risk of
adverse maternal and fetal outcomes for normal
weight (BMI 18.5–24.9 kg/m2), overweight (BMI
25–29.9 kg/m2) and obese (BMI ≥30 kg/m2)
women
ii. Assess if adherence in pregnancy to IOM weight
gain recommendations minimises adverse pregnancy
outcomes in normal weight, overweight and obese
women
iii. Identify the prognostic factors for gestational weight
gain based on patient characteristics such as pre-
pregnancy BMI, age, ethnicity, socioeconomic status,
parity, ethnicity, smoking, diet and lifestyle
iv. Undertake network meta-analysis to produce a rank
order of interventions
v. Assess the cost effectiveness of the various
interventions in pregnancy using model-based full
economic evaluation with value of information
(VOI) analysis
Methods/design
Our IPD meta-analytical approach will follow existing
guidelines, and our output will comply with the PRISMA
statement and adhere to recent reporting guidelines for
IPD meta-analysis.
Search strategy
We will update the literature search to identify new trials
published since the completion of our systematic review
(HTA No. 09/27/06) on effects of weight management in-
terventions in pregnancy [21]. The following databases
will be searched: MEDLINE, EMBASE, BIOSIS, LILACS,
Pascal, Science Citation Index, Cochrane Database of Sys-
tematic Reviews (CDSR), Cochrane Central Register of
Controlled Trials (CENTRAL), Database of Abstracts of
Reviews of Effects (DARE) and Health Technology Assess-
ment Database (HTA). Other relevant databases including
the Inside Conferences, Systems for Information in Grey
Literature (SIGLE), Dissertation Abstracts, and Clinical
Trials.gov will be searched. Internet searches will include
specialist search gateways (such as OMNI: http://omni.ac.
uk), general search engines (such as Google: https://www.
google.co.uk), and meta-search engines (such as Copernic:
http://www.copernic.com). In addition, information on
studies in progress, unpublished research, research re-
ported in the grey literature, and details from commercial
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applied. The search will be updated 1 year before the end
of the project to avoid missing recently published studies.Establishment of the International Weight Management
in Pregnancy IPD Collaboration
We contacted researchers who have published trials on
weight management interventions in pregnancy and
established the International Weight Management in
Pregnancy (i-WIP) IPD Collaborative Network [21].
There has been an overwhelming interest for a joint
endeavour in this field. The network, supported by
WHO (World Health Organization), is a global effort
in bringing together researchers, clinicians and epide-
miologists from 14 countries (https://kamolo.org.ar/
iwipipd) Thirty-six collaborators have joined the network
to date providing access to anonymised individual data of
9,344 women (Table 1).Inclusion and exclusion criteria
Randomised controlled trials evaluating diet- and phys-
ical activity-based interventions in pregnancy compared
to normal antenatal care are eligible for inclusion. Un-
derweight women (BMI <18.5 kg/m2) and women with
contra-indications to limit gestational weight gain will
be excluded. The interventions include those that are
based on diet, physical activity, or a mixed approach
comprising diet and physical activity with or without be-
havioural modification techniques. Studies assessing
weight-reducing drugs or surgical interventions will not
be included.Outcome measures
The primary outcome measures are (i) maternal weight
gain in pregnancy and (ii) composite adverse maternal
and fetal outcomes. Gestational weight gain is defined as
the change in weight from the first scheduled visit to the
weight measured before delivery. The composite out-
come includes those components that are critically im-
portant to clinical practice and whose underlying biology
is similar [24]. The individual components were defined
according to NICE guidelines [25,26] and identified by a
four-round Delphi survey. The first two rounds of the
survey identified the clinically important outcomes with
input from experts [27]. The subsequent two rounds of
the Delphi survey were completed by i-WIP collabora-
tors to ensure that the outcomes were clinically relevant,
of equal importance, occur with similar frequency and
have the same direction of effect with the intervention
(Table 2). We will include in our analysis those compo-
nents for which robust data is available across the indi-
vidual studies.Study quality assessment and data collection
A bespoke database will be set up and authors will be
allowed to supply data in whatever way convenient to
them. We will consider all recorded variables, even those
not reported in the published studies. The quality of
each trial will be assessed [28,29] to evaluate the integ-
rity of the randomisation and follow-up procedure. We
will evaluate the risk of bias in individual studies by con-
sidering six items used in the Cochrane risk of bias tool:
sequence generation, allocation concealment, blinding,
incomplete outcome data, selective outcome reporting,
and other potential sources of bias.Sample size considerations
Although no formal sample size requirements are neces-
sary for the meta-analysis, we have considered the po-
tential power of our IPD meta-analysis in comparison to
single trials in this field to detect clinically important ef-
fects in each subgroup separately (Table 3). All calcula-
tions relate to a type I error of 5%, a power of 80% and a
loss to follow-up of 5%. We chose a reduction of 2.5 kg
in gestational weight gain as the minimally important
difference (MID), since it was associated with improve-
ment in obstetric outcomes [12]. Our sample size will be
over 9,000 women. For maternal weight gain, the sample
size required for all subgroups is 300 or less. Given the
large sample size available, it is highly likely that the
study is powered to detect important differences bet-
ween subgroups (that is, to identify genuine factors that
modify treatment effect). This will allow us to detect
interaction terms as small as about 30% of the size of
the overall treatment effect. So, if the overall interven-
tion effect is a reduction in weight gain of 2.5 kg, then
our IPD meta-analysis will have 80% power to detect an
interaction term of about 2.5 × 0.3 = 0.75 or above (e.g. a
difference in intervention effect of 0.75 kg between
obese and normal weight women).
For the composite outcome of adverse maternal and
fetal outcomes, we calculated the sample size needed to
detect an intervention effect of a 30% reduction in ad-
verse pregnancy outcome. Our estimates of the standard
deviation (SD) of the control group and the risk of com-
posite pregnancy outcome were obtained from the data
of primary studies included in our systematic review.
The largest sample size required is 2,330 for the adverse
pregnancy outcome in the normal BMI group. Of our
5,000 women, we expect over half to be in this normal
category. For overweight and obese women, the sample
size required for the adverse pregnancy outcome is 1,290
and 770 respectively (Table 4).
Table 1 shows a comparison of existing evidence on ef-
fectiveness of weight management interventions in preg-
nancy and the proposed IPD meta-analysis.
Table 1 Studies with provisional support and consideration to share individual patient data
Study year Country Study characteristics Outcomes Sample
sizeMaternal Fetal
Althuizen 2012 Netherlands Ethnically diverse; no BMI restrictions; age, nr; GA
at inclusion, <14 weeks; glucose status, nr; other
risk factors, nr
GWG, GDM,
preterm delivery,
CS
Birth weight, macrosomia 269
Barakat 2009 Spain Caucasian; BMI restrictions, nr; age, 25–35 years;
GA at inclusion, nr (total at least 26 weeks
intervention); glucose status, nr; no known
pre-existing health problems
GWG, GA, preterm
delivery
Birth weight, LGA, SGA, AS,
macrosomia (>4,000 g)
142
Barakat 2011 Spain Spanish (White); BMI restrictions, nr; age, 23–38
years; GA at inclusion, first prenatal visit; glucose
status, nr; no known pre-existing health problems
GWG, GA CS,
vaginal delivery
Birth weight, AS 80
Barakat 2013 Spain Caucasian; no BMI restrictions; age, nr; GA at
inclusion, <10 weeks; glucose status, nr; no
known pre-existing health problems
GWG, GA, GDM,
PIH, preterm
delivery
Birth weight, AS 765
Bogaerts 2012 Belgium Ethnically diverse; BMI, ≥29 kg/m2; age, nr; GA
at inclusion, <15 weeks; nondiabetic; other risk
factors, nr
GWG, GA, PE, PIH,
GDM, IOL, CS,
vaginal delivery
Birth weight, AS 197
Cavalcante 2009 Brazil Race, nr; no morbid obesity; age restrictions, nr;
GA at inclusion, 16–20 weeks; glucose status, nr;
no known pre-existing health problems
GWG, preterm
delivery
Birth weight 71
Clapp 1997 USA Race, nr; no morbid obesity; age restrictions, nr;
GA at inclusion, 8 weeks; glucose status, nr; no
known pre-existing health problems
GWG Birth weight 51
Clapp 2000 USA Race, nr; no morbid obesity; age restrictions, nr;
GA at inclusion, 8 weeks; glucose status, nr; no
known pre-existing health problems
GWG, GA Birth weight 12
Dodd 2014 Australia Race, nr; BMI, ≥25 kg/m2; age restrictions, nr; GA
at inclusion, <20 weeks; nondiabetic; other risk
factors, nr
PE, PIH, GDM, IOL,
CS, preterm
delivery
LGA, macrosomia (>4,000 g),
hypoglycaemia, shoulder dystocia,
admission to NICU
1,582
El Beltagy 2013 Egypt Race, nr; BMI, obese; age restrictions, nr; GA at
inclusion, first antenatal visit; glucose status, nr;
other risk factors, nr
GWG, GDM Birth weight, macrosomia 100
Grant 2013 Canada Race, predominantly non-Caucasian; BMI
restrictions, nr; age, >18 years, GA at inclusion,
nr; glucose status, impaired glucose tolerance or
GDM; no known pre-existing health problems
GWG Birth weight, macrosomia 47
Guelinckx 2010 Belgium Caucasian; BMI, ≥29 kg/m2; age restrictions, nr;
GA at inclusion, <15 weeks; nondiabetic; no
known pre-existing health problems
GWG, GA, PE, PIH,
IOL, CS
Birth weight, LGA 85
Haakstad 2011 Norway Race, nr; BMI restrictions, nr; age restrictions, nr;
GA at inclusion, <24 weeks; glucose status, nr;
no known pre-existing health problems
GWG 105
Hui 2006 Canada Ethnically diverse; BMI restrictions, nr; age
restrictions, nr; GA at inclusion, <26 weeks;
nondiabetic; no known pre-existing health
problems
GWG, GA, GDM Birth weight, LGA 45
Hui 2011 Canada Race, nr; BMI restrictions, nr; age restrictions, nr;
GA at inclusion, 20–26 weeks; nondiabetic; no
known pre-existing health problems
GWG, GA, GDM,
CS
Birth weight, LGA 224
Jackson 2010 USA Ethnically diverse; BMI restrictions, nr;
age, >18 years; GA at inclusion, <26 weeks;
glucose status, nr; other risk factors, nr
GWG 321
Jeffries 2009 Australia Race, nr; BMI restrictions, none; age, >18 to
<45 years, GA at inclusion, <14 weeks;
nondiabetic; other risk factors, nr
GWG, PE, PIH,
GDM , preterm
delivery, CS
Birth weight, LGA, SGA,
hypoglycaemia, shoulder dystocia
236
Khaledan 2010 Iran Race, nr; BMI restrictions, nr; age restrictions, nr;
GA at inclusion, 24–32 weeks; no diabetes
mellitus type 1 (DM1) with poor control; no
known pre-existing health problems
GWG, GA, CS Birth weight 39
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Khoury 2005 Norway Caucasian; BMI, 19–32 kg/m2; age, 21–38 years;
GA at inclusion, 17–20 weeks; nondiabetic; no
known pre-existing health problems
GWG, PE, preterm
delivery
Birth weight, SGA, intra-uterine
death
290
Luoto 2011 Finland Race, nr; BMI, >17 kg/m2; age, >18 years; GA at
inclusion, 8–12 weeks; nondiabetic; no known
pre-existing health problems
GWG, GA, PE,
GDM
Birth weight, LGA, SGA 399
Nascimento 2011 Brazil Race, nr; BMI, >26 kg/m2; age >18 years; GA at
inclusion, 14–24 weeks; nondiabetic; no known
pre-existing health problems
GWG, PIH, GDM,
CS
Birth weight, AS, LGA, SGA 82
Ong 2009 Australia Race, nr; obese; age restrictions, nr; GA at
inclusion, 18 weeks; nondiabetic; other risk
factors, nr
GWG 12
Oostdam 2012 Netherlands Ethnically diverse; BMI, ≥25.0 kg/m2; age,
>18 years; GA at inclusion, <20 weeks;
nondiabetic; no known pre-existing health
problems
GWG, GDM Birth weight 124
Phelan 2011 USA Ethnically diverse; BMI, ≥19.8–26.0 kg/m2; age
>18 years; GA at inclusion, 10–16 weeks; glucose
status, nr; no known pre-existing health problems
GWG, GA, PE, PIH,
GDM, preterm
delivery, CS
Birth weight, macrosomia, birth
weight <2,500 g
401
Poston 2013 UK Race, nr; BMI, ≥30 kg/m2; age restrictions, nr; GA
at inclusion, >15+0 weeks and <17+6; nondiabetic;
no known pre-existing health problems
GA, GWG, PE,
GDM, mode of
delivery
Birth weight, macrosomia, still
birth
183
Prevedel 2003 Brazil Race, nr; BMI restrictions, nr; age restrictions, nr
(primiparous or adolescents); GA at inclusion,
16–20 weeks; glucose status, nr; no known
pre-existing health problems
GWG, preterm
delivery
Birth weight, SGA 132
Rauh 2013 Germany Race, nr; BMI, ≥18.5 kg/m2; age, ≥18 years; GA
at inclusion, <18 weeks; nondiabetic; no known
pre-existing health problems
GWG, GDM, IOL,
CS, preterm
delivery
LGA, SGA 250
Sagedal 2014 Norway Race, nr; BMI, ≥19 kg/m2; age, ≥18 years; GA
at inclusion, <20 weeks; nondiabetic; no known
pre-existing health problems
GWG, GDM, CS LGA 600
Stafne 2012 Norway White; no BMI restrictions; age, >18 years; GA at
inclusion, 18–22 weeks; nondiabetic; no known
pre-existing health problems
GA, PE, PIH, GDM,
CS
Birth weight, AS, LGA, admission
to NICU
124
Vesco 2013 USA Race, nr; BMI, ≥30 kg/m2; age, nr; GA at
inclusion, <20 weeks; nondiabetic; no known
pre-existing health problems
GWG, GA, PE, PIH,
GDM, CS, preterm
delivery
Birth weight, LGA, SGA,
macrosomia (4,000 g)
114
Vinter 2011 Denmark Caucasian; BMI, 30–45 kg/m2; age, 18–40 years;
GA at inclusion, 10–14 weeks; nondiabetic; no
known pre-existing health problems
GWG, PE, PIH,
GDM, CS
LGA, admission to NICU 855
Vitolo 2011 Brazil Race, nr; BMI restrictions, none; age, <35 years;
GA at inclusion, 10–29 weeks; nondiabetic; no
known pre-existing health problems
GWG, PE, PIH,
GDM, preterm
birth
Birth weight 315
Walsch 2012 Ireland Race, nr; BMI restrictions, nr; age, >18 years; GA
at inclusion, <18 weeks; nondiabetic; no known
pre-existing health problems
GWG, GA, preterm
delivery, IOL, CS
Birth weight, macrosomia 304
Wolff 2008 Denmark Caucasian; BMI, ≥30 kg/m2; age, >18
to <45 years; GA at inclusion, <18 weeks;
nondiabetic; no known pre-existing health
problems
GWG PE, PIH,
GDM , CS
Birth weight 800
Yeo 2012 USA Ethnically diverse; BMI, >19.8 kg/m2; no age
restrictions; GA at inclusion, 18 weeks;
nondiabetic; no known pre-existing health
problems
GWG, PE, PIH Birth weight 17
AS Apgar score, CS caesarean section, GA gestational age, GDM gestational diabetes mellitus, GWG gestational weight gain, IOL induction of labour, LGA large for
gestational age, NICU Neonatal Intensive Care Unit, nr not reported, PE pre-eclampsia, PIH pregnancy-induced hypertension, RDS respiratory distress syndrome,
SGA small for gestational age.
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Table 2 Critically important maternal and fetal outcomes
in the IPD meta-analysis of weight management
interventions identified by the Delphi survey
Maternal outcomes Fetal outcomes
Pre-eclampsia Intrauterine death
Pregnancy induced hypertension Small for gestational age
Gestational diabetes mellitus Large for gestational age
Preterm delivery Admission to NICU
Caesarean section Shoulder dystocia
Thromboembolism >1 perinatal complication
Admission to high dependency unit/
intensive treatment unit
Birth trauma
Weight gain in pregnancy Long-term neurological sequelae
Long-term metabolic sequelae
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Summarising the overall effect of weight management
interventions
First, we will summarise the overall effect of each inter-
vention (in relation to each outcome) across the entire
set of available patient data. Meta-analyses of the ef-
fectiveness of weight management interventions in preg-
nancy will be performed for the weight-related and
composite adverse maternal and fetal outcomes. We will
include all patients ever randomised and will base our
analysis on the intention to treat principle. Women with
glucose intolerance will be excluded in the analysis of
composite adverse pregnancy outcomes, as gestational
diabetes is one of the components of the composite
outcome.
All studies will be reanalysed separately and the original
authors asked to confirm the individual study results, andTable 3 Comparison of existing evidence on effectiveness of
meta-analysis
Characteristics
Consistent inclusion and exclusion criteria e.g. BMI, risk status
Assessment of effect of prognostic factors on treatment effect e.g. diabetic s
chronic hypertension
Missing data observed and accounted at individual level
All critically important maternal and fetal outcomes considered
Potential for sufficient power to assess for differential treatment effect across
e.g. BMI, ethnicity, race, parity
Standardisation of statistical analysis across studies
Correlation between multiple end points accounted e.g. each participant pro
data on gestational weight gain in various trimesters and weight retention p
Up to date follow-up information, potentially longer than that used in the or
study publicationany discrepancies will be resolved. Then, for each inter-
vention type and outcome separately, we will perform
either a one-step or a two-step IPD meta-analysis to ob-
tain the pooled intervention effect. The one-step ap-
proach analyses the IPD from all studies simultaneously,
whilst accounting for the clustering of patients within
studies. In contrast, the two-step approach first esti-
mates the intervention effect from the IPD in each study
separately and then pools them using a conventional
meta-analysis of the intervention effect estimates ob-
tained. One-step and two-step meta-analyses usually
give similar results but, where possible, will undertake
both to ensure that conclusions remain robust to the
choice of method [23,30].
Given the heterogeneity identified in our previous re-
view [21], we also expect to observe significant hetero-
geneity in the IPD meta-analysis. Thus, we will use a
random effects meta-analysis approach, which allows for
between-study heterogeneity in intervention effect. Het-
erogeneity will be summarised using the I-squared statis-
tic (which provides the proportion of total variability
that is due to between-study heterogeneity) and the esti-
mated between-study variance (‘tau-squared’), obtained
using restricted maximum likelihood estimation.
For continuous outcomes, we will aim to synthesise
mean differences (potentially standardised if outcome
scales differ substantially) and adjust for baseline values
using analysis of covariance, as recommended [31]. For
binary outcomes, we will aim to synthesise relative risks
or odds ratios, with the binomial nature suitably mod-
elled using, for example, a one-step logistic regression
adjusting for clustering. For any time-to-event outcome,
we will aim to fit a Cox regression model (after checking
for proportional hazards) in each study and then synthe-
sise the estimated hazard ratios obtained. At the study-weight management interventions and the proposed IPD
Existing systematic
reviews
Published and
ongoing primary
studies
Proposed IPD
meta-analysis
x √ √
tatus, x √ √
x √ √
√ x √
groups x x √
x N/A √
viding
ostpartum
x √ √
iginal x x √
Table 4 Sample size estimations evaluating the effect of weight management interventions
Subgroups Control group SD Sample size required to
detect a 2.5-kg reduction
in gestational weight gain
Control group: probability
of adverse maternal and
fetal outcomes
Sample size required to
detect a 30% reduction
in adverse maternal and
fetal outcomes
BMI Obese 7.5 300 0.30 770
Overweight 7.5 300 0.20 1,290
Normal 5.1 140 0.12 2,330
Age <20 years 7.12 270
≥20 years 5.87 184
Ethnicity Caucasian 3.4 64
Asian 3.8 78
African 5.1 140
Parity <1 6.28 212
≥1 6.68 238
Risk factors like diabetes High risk 6.81 248
Low risk 6.67 236
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will be assumed normally distributed allowing us to esti-
mate the average intervention effect and its confidence
interval, and the between-study variance (‘tau-squared’).
To reveal the impact of heterogeneity more clearly, we
will also calculate a 95% prediction interval for the in-
tervention effect when applied in an individual clinical
setting [32].
Examining heterogeneity and estimating intervention
effects within each subgroup
To consider the causes of heterogeneity and factors that
may modify the intervention effect for each outcome, for
each weight management intervention we will meet the
primary objectives of our project by performing the
pre-specified subgroup analyses by BMI, age; ethnicity,
parity, risk status of medical comorbidities in preg-
nancy risk; and type of intervention. To obtain the
summary intervention effects in each subgroup, we will
use the same random-effects meta-analysis approach as
described above. Subgroup analyses, if not carefully
planned, can lead to misleading results e.g. due to the
play of chance with multiple testing [32]. Thus caution
will be used in the interpretation of the collective set of
subgroup results, and adjustment for multiple testing
will be considered.
It is important to calculate the difference in intervention
effect between subgroups, to ascertain if any observed dif-
ferences are due to chance. This will be undertaken by ex-
tending the one-stage meta-analysis framework to include
treatment-covariate interaction terms, which provide the
change in intervention effect for a 1-unit change in the
covariate. In doing so, we will ensure that we estimatethe pooled within-trial interaction of interest separately
from the across-trial (meta-regression) interaction, as
recommended because the former is the desired infor-
mation as it is based solely on patient-level information
[33,34]. Between-study heterogeneity in the within-trial
treatment-covariate will also be measured, summarised
and, if necessary, accounted for in the analysis. Continu-
ous covariates, such as BMI and age, will be analysed on
their continuous scale, rather than categorisation [35].
However, to translate the results clinically, after the ana-
lysis we will report the effect of the covariate-treatment
interaction on the intervention effect at clinically rele-
vant covariate values, such normal weight values, over-
weight values, and obese values, and those aged under
or over 18.
As a secondary analysis, we will evaluate the associ-
ation between weight gain in pregnancy and adverse ma-
ternal and fetal outcomes in normal weight, overweight,
and obese women. For each group separately and each
outcome, we will fit a suitable regression model that ac-
counts for clustering of patient within studies and quan-
tifies how each 1-unit increase in weight gain changes
the risk of a poor outcome. As the relationship is likely
to be non-linear, we will consider non-linear trends be-
tween weight gain and outcome using fractional polyno-
mial terms [35]. For each type of outcome, a suitable
model will be used such as linear regression for continu-
ous outcomes, or logistic regression for binary outcomes.
The model will account for the clustering of patients
within trials, and their treatment group allocation. Fur-
ther, we will consider whether the association between
weight gain and outcome interacts with whether a pa-
tient is in the intervention group or not.
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change in pregnancy
In secondary analyses, we will also evaluate those vari-
ables that may have a prognostic effect on gestational
weight gain including age, ethnicity, underlying medical
conditions like diabetes, parity, type and duration of
intervention, mental health, and socioeconomic status
[36]. For all candidate prognostic factors (predictors), we
will perform separate analyses in each BMI cohort (nor-
mal, overweight, and obese) and analyse on the whole
meta-analysis database, adjusting again for the clustering
of patients within studies and accounting for heterogen-
eity as necessary. To obtain adjusted prognostic factor
results, multivariable models will be fitted including all
variables of interest, to ascertain which have independ-
ent prognostic value.
Network meta-analyses
We will rank the interventions according to their ef-
fectiveness using a network meta-analysis approach [37].
Under the assumption that the sets of trials in each
meta-analysis are comparable, an indirect comparison
will be carried out by calculating the difference in treat-
ment effect sizes for all interventions (to get say A vs B
using A vs C minus B vs C). Within-trial randomised
comparisons of each study will be preserved. Our net-
work meta-analyses will be undertaken in a frequen-
tist framework using multivariate meta-analysis models
within the STATA modules ‘network’ [38,39], which al-
lows within-study correlations (between pairs of effect
estimates from the same study) and between-study corre-
lations to be accounted for as necessary. The consistency
assumption will also be examined in this framework, for
example, by comparing the difference in direct and indir-
ect effect estimates and comparing the fit of consistency
and inconsistency models. We note that where indirect
comparisons have been compared to direct comparisons,
over 95% concordance has been found [35,40]. Ranking
will be achieved by assuming flat, uninformative prior
distributions for all parameters, and thus assuming the
multivariate normal sampling distribution of the pooled
treatment effects is a posterior distribution with mean
and variance equal to the frequentist estimates and
variance-covariance matrix. Thus, approximate Bayesian
inferences are then possible. One thousand draws will
be made from the posterior distribution, and the treat-
ments will be ordered according to the probability
(across all draws) that they are the most effective on
average.
Exploration of sources of bias: unavailable data and
publication bias
We will explore the potential for, and possible impact of,
both publication bias and unavailable data, according torecent guidelines [41]. For each analysis containing ten
or more studies, the likelihood of publication bias will
be investigated through the construction of contour-
enhanced funnel plots and appropriate statistical tests
for ‘small-study effects’; that is, the tendency for smaller
studies to provide more positive findings.
In addition, for all studies where IPD were not pro-
vided to us, we will seek to extract suitable aggregate
data from their study publications (such aggregate data
has already been extracted from our previous HTA re-
view). Where possible, we will then, using the two-step
meta-analysis framework, combine the IPD trials with
the aggregate data from other trials using suitable statis-
tical methods to examine if conclusions change by the
inclusion of additional trials [33,34]. If the inclusion of
studies lacking IPD seems to have an important statis-
tical or clinical impact, we will compare the characteris-
tics of the studies with IPD and of those without to see
if there are any key differences (such as in their quality,
follow-up length, statistical methods). We recognise, how-
ever, that this approach is likely to only be achievable
when examining the overall treatment effect, and our
main IPD analyses of the subgroup effects are unlikely to
be able to include any suitable aggregate data for subgroup
effects from non-IPD studies (the very reason why we
have sought IPD for meta-analysis).Health economic evaluation
We will develop a decision analytic simulation model
as a framework for conducting cost-effectiveness and
cost-utility analyses and associated value of information
analyses [42,43]. The economic evaluations will inform
current treatment policy in this clinical area, whilst the
value of information component will serve to highlight
future research needs and agendas and inform possible
future research funding decisions.
The main objective of the evaluation will be to deter-
mine the characteristics of the weight management inter-
vention(s) that are most cost-effective. Hence, the range of
options (in terms of duration, frequency and intensity) for
which trial data exist will be investigated.
An incremental approach will be adopted with a focus
on additional costs and gain in benefits associated with a
move away from current practice to alternative treat-
ment strategies. The cost-effectiveness component of the
work will report results in terms of an incremental cost-
effectiveness ratio (ICER) of cost per unit of benefit
gained, measured in appropriate clinical and economic-
ally relevant outcome measures.
Some limited quality of life data potentially suitable
for use in a cost-utility framework are available from
published sources [44,45], and so the economic evalu-
ation will attempt additionally to present results in terms
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The results will be presented using cost-effectiveness
acceptability curves to reflect sampling variation and un-
certainties in the appropriate threshold cost-effectiveness
value. We shall also include a value of information analysis
to quantify the total uncertainty in terms of the value of
removing that uncertainty. In addition to this probabilistic
sensitivity analysis on our base-case model, we shall in-
clude a range of alternative analyses to explore the robust-
ness of these results to plausible variations in key
assumptions and variations in the analytical methods used
and to consider the broader issue of the generalisability of
the results.Discussion
The IPD meta-analysis will allow us to identify and sub-
sequently target the interventions to those groups that
show clear benefit with weight management in preg-
nancy. It has greater power to detect any differential
treatment effect across groups as it can model individual
risk status (prognostic factor values) across participants
within trials and thus explain variability in outcomes at
the patient-level [16]. In contrast, aggregate data meta-
analysis can only model average risk status values across
studies and thus only explain variation in summary out-
comes at the study-level. Availability of IPD alleviates
the need to use published results and is thus less likely
to be affected by selective and biased reporting than an
aggregate data meta-analysis. It also has the potential
to assess longer follow-up and include more partici-
pants and more outcomes than reported in the original
publication.
Weight gain in pregnancy varies with age, ethnicity,
and parity. Pregnancy during adolescence may alter nor-
mal growth processes and increase the risk of the mo-
thers becoming overweight or obese [46]. Adolescent
mothers also retain more weight postpartum than ma-
ture control subjects [46]. Therefore, inclusion of a large
number of pregnant adolescents may overestimate post-
partum weight changes or the risk of becoming over-
weight and thus bias estimates for mature women. In
the US, immigrant women are known to have less gesta-
tional weight gain but the same rate of complications in
pregnancy compared to the domestic population [47].
Ethnic differences in the relationship between weight
gain and complications need further investigation.
The trials identified in our previous HTA systematic
review on diet and lifestyle interventions in pregnancy
were powered to detect an overall treatment effect,
but not to detect a subgroup effect. The costs and
time to undertake a new trial for this purpose would
be immense.One of the key recommendations that arose from the
study level meta-analysis of dietary and physical activity
interventions in pregnancy was the need to synthesise
patient level data to assess any differential effect of the
benefits observed with interventions in various sub-
groups [21,27]. Such questions are difficult to answer
using extracted results from trial publications, as patient-
level information is no longer available and subgroup
effects (‘treatment-covariate interactions’) are rarely re-
ported in sufficient detail. Furthermore, meta-regression
examining the across-trial association between overall
treatment effect and average patient characteristics (e.g.
mean age) generally has low power to detect genuine
subgroup effects and is also prone to study-level con-
founding [33,48].
We have chosen composite maternal and fetal out-
comes to assess the effects of interventions in preg-
nancy as it is difficult to identify one clinically important
outcome. The components of the composite maternal
and fetal outcomes were identified by Delphic survey
of experts ensuring face validity of the components.
Through our systematic review of randomised trials,
we have shown that there is an association between
change in the individual outcomes in the same direc-
tion and weight management interventions, thereby en-
suring content validity of the chosen composite outcome
measure [27].
Our collaborative group has provisional support so
far to include over 9,000 women. In contrast, single
trials in this field have so far included much smaller
number of women, with a median number of 137 women
(smallest n =12; largest n =1,500). Thus, there is over a
50-fold increase in the sample size for our IPD project
compared to the median number in the trials. We rec-
ognise that there is additional variability in an IPD
meta-analysis due to clustering of patients within stu-
dies and heterogeneity in effects across studies. How-
ever, compared to a single trial that typically has 137
women, the provision of 9,000 patients within our IPD
meta-analysis will dramatically improve upon single-
trial research.
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